Review



generation therapeutic protein drug class  (Pieris Pharmaceuticals)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Pieris Pharmaceuticals generation therapeutic protein drug class
    Generation Therapeutic Protein Drug Class, supplied by Pieris Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/generation+therapeutic+protein+drug+class/class+drug+generation+protein+therapeutic/sec_filing____1583648_slash_000119312516425868_slash_d106211dex991-24-8-0
    Average 86 stars, based on 1 article reviews
    generation therapeutic protein drug class - by Bioz Stars, 2026-10
    86/100 stars

    Images

    Related Articles

    other:

    Article Title: EX-99.1
    Article Snippet: Roche n.d. Daiichi Sankyo n.d. n.d. n.d. n.d. Sanofi P. auruginosa inf.

    Biomarker Discovery:

    Article Title: EX-99.1
    Article Snippet: .. Pieris Pharmaceuticals Corporate Profile We own a next generation therapeutic protein drug class, Anticalins® Addressing validated targets in a unique and transformative way Clinical validation demonstrates excellent drug-like properties Our rapidly advancing proprietary pipeline addresses large markets Immuno-oncology bispecific tailored for the tumor micro-environment Inhaled Anticalin to treat uncontrolled asthma Half-life-optimized Anticalin to treat anemia We have an excellent cadre of investors and R&D partners OrbiMed Advisors (18%), Tekla Capital Management (10%), Lombard Odier (7%), Omega Funds (6%) Roche, Sanofi, Daiichi, etc: >$50 million in non-dilutive funding to date and combined milestone potential of $>700 million Our unique multispecifics platform provides broad potential for attractive partnerships in immuno-oncology and other areas Non-confidential ..

    Article Title: EX-99.1
    Article Snippet: Pieris Pharmaceuticals Corporate Profile We own a next generation therapeutic protein drug class, Anticalins® Addressing validated targets in a unique and transformative way Clinical validation demonstrates excellent drug-like properties Our rapidly advancing proprietary pipeline addresses large markets Immuno-oncology bispecific tailored for the tumor micro-environment Inhaled Anticalin to treat uncontrolled asthma Half-life-optimized Anticalin to treat anemia We have an excellent cadre of investors and R&D partners OrbiMed Advisors (18%), Tekla Capital Management (10%), Lombard Odier (7%), Omega Funds (6%) Roche, Sanofi, Daiichi, etc: >$50 million in non-dilutive funding to date and combined milestone potential of $>700 million Our unique multispecifics platform provides broad potential for attractive partnerships in immuno-oncology and other areas Non-confidential .. Pieris Pharmaceuticals Corporate Profile We own a next generation therapeutic protein drug class, Anticalins® Addressing validated targets in a unique and transformative way Clinical validation demonstrates excellent drug-like properties Our rapidly advancing proprietary pipeline addresses large markets Immuno-oncology bispecific tailored for the tumor micro-environment Inhaled Anticalin to treat uncontrolled asthma Half-life-optimized Anticalin to treat anemia We have an excellent cadre of investors and R&D partners OrbiMed Advisors (18%), Tekla Capital Management (10%), Lombard Odier (7%), Omega Funds (6%) Roche, Sanofi, Daiichi, etc: >$50 million in non-dilutive funding to date and combined milestone potential of $>700 million Our unique multispecifics platform provides broad potential for attractive partnerships in immuno-oncology and other areas Non-confidential Anticalin Product Pipeline Product Target(s) Indication Partner Discovery Preclinical IND-enabling Ph 1 - 1b/2a PRS-080 Hepcidin Anemia PRS-060 IL4Ra Asthma PRS-343 CD137/HER2 Immuno-Oncology PRS-342 CD137/GPC3 PRS300s n.d/n.d. ..



    Similar Products

    generation therapeutic protein drug class  (Pieris Pharmaceuticals)
    86
    Pieris Pharmaceuticals generation therapeutic protein drug class
    Generation Therapeutic Protein Drug Class, supplied by Pieris Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/generation+therapeutic+protein+drug+class/class+drug+generation+protein+therapeutic/sec_filing____1583648_slash_000119312516425868_slash_d106211dex991-24-8-0
    Average 86 stars, based on 1 article reviews
    generation therapeutic protein drug class - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier

    Image Search Results